PCC Rokita Second Quarter 2024 Earnings: EPS: zł1.50 (vs zł0.76 in 2Q 2023)
PCC Rokita (WSE:PCR) Second Quarter 2024 Results
Key Financial Results
- Revenue: zł508.4m (down 9.3% from 2Q 2023).
- Net income: zł29.7m (up 97% from 2Q 2023).
- Profit margin: 5.8% (up from 2.7% in 2Q 2023). The increase in margin was driven by lower expenses.
- EPS: zł1.50 (up from zł0.76 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
PCC Rokita Earnings Insights
Looking ahead, revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe.
Performance of the market in Poland.
The company's shares are down 1.9% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 2 warning signs for PCC Rokita (1 is a bit unpleasant!) that you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:PCR
PCC Rokita
Designs, produces, and sells chemical products in Poland and internationally.
Flawless balance sheet and fair value.